On November 10, Edwards Lifesciences recorded an Intraday Rise of 3.02% in Regular Trading, trading at $105.16 per share with turnover of $368 million.

The move coincided with a fresh analyst target increase to $115 from $101, reinforcing constructive sentiment after the company recently reported quarterly results above expectations.

Edwards Lifesciences posted adjusted EPS of $0.80 for the September quarter on revenue of $1.716 billion, ahead of consensus forecasts of $0.74 and $1.676 billion. The company also narrowed its full-year adjusted EPS guidance to $2.97 to $3.05, versus market expectations near $3. Earlier, another brokerage upgraded the stock to buy and lifted its target price to $113, while positive clinical and product milestones in structural heart devices have continued to support the broader growth narrative.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)